LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights increased guidance across multiple financial metrics, including revenue and EPS, alongside strategic growth in cardiopulmonary and epilepsy segments. The Q&A section reveals positive analyst sentiment and confidence in management's ability to execute on guidance, with no major risks identified. The company's proactive approach to reimbursement changes and product launches further supports a positive outlook. Despite conservative assumptions for 2026, the current guidance and market strategy suggest a likely positive stock price movement in the near term.
Key Financial Performance
Cardiopulmonary Segment Revenue (Q4 2025) $207 million, an increase of 10% versus Q4 2024. Growth driven by an increase in Essenz placements and sustained favorable price premiums. Some planned placements shifted into 2026, moderating Q4 contribution.
Cardiopulmonary Segment Revenue (Full Year 2025) $785 million, grew 13%. Growth driven by mid-single-digit growth in heart-lung machine revenue and mid-teens growth in cardiopulmonary consumables revenue due to market share gains, procedure growth, and price.
Epilepsy Revenue (Q4 2025) Increased 9% versus Q4 2024. Growth across all regions, with Europe and Rest of World regions increasing 17% combined, and U.S. epilepsy revenue increasing 8% year-over-year. Reflects strong commercial execution globally.
Epilepsy Revenue (Full Year 2025) Grew 6%. Europe and Rest of World regions grew 13% combined, while U.S. epilepsy revenue grew 5% year-over-year. Growth supported by impactful clinical evidence, innovation, and improved reimbursement dynamics.
Adjusted Gross Margin (Q4 2025) 68%, in line with Q4 2024. Favorable product mix and pricing offset by unfavorable currency changes and tariff impacts.
Adjusted SG&A Expense (Q4 2025) $131 million, compared to $122 million in Q4 2024. SG&A as a percent of net revenue was 36%, down from 38% in Q4 2024, driven by fixed cost leverage.
Adjusted R&D Expense (Q4 2025) $49 million, compared to $40 million in Q4 2024. R&D as a percent of net revenue was 14%, up from 13% in Q4 2024, driven by OSA and core product development investments.
Adjusted Operating Income (Q4 2025) $64 million, compared to $56 million in Q4 2024. Adjusted operating income margin was 18%, up from 17% in Q4 2024, driven by revenue growth and operating leverage from fixed costs.
Adjusted Diluted Earnings Per Share (Q4 2025) $0.86, compared to $0.81 in Q4 2024. Increase driven by adjusted operating income and effective cost management.
Cash Balance (End of 2025) $636 million, up from $429 million at year-end 2024. Increase reflects improvements in operating cash flows and release of $295 million of restricted cash.
Total Debt (End of 2025) $377 million, compared to $628 million at year-end 2024. Reduction due to $200 million early repayment of term facilities and $58 million repayment of 2025 convertible notes.
Adjusted Free Cash Flow (Q4 2025) $53 million, compared to $62 million in Q4 2024. Decrease driven by increased capital spend.
Adjusted Free Cash Flow (Full Year 2025) $183 million, up from $163 million in 2024. Increase driven by stronger operating results and working capital improvements.
Capital Spend (Full Year 2025) $81 million, compared to $47 million in 2024. Increase driven by IT investments and cardiopulmonary capacity expansion initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Obstructive Sleep Apnea (OSA): LivaNova is entering the OSA market with differentiated technology and clinical evidence. The company expects PMA approval for the clinical trial device in the first half of 2026, followed by a broader commercial launch in 2027.
Epilepsy Digital Health Platform: FDA approval was received for a cloud-based digital health platform, with a limited rollout planned for 2026 and a full launch in 2027. This platform will integrate with a Bluetooth-enabled generator to improve patient and clinician workflows.
Cardiopulmonary Segment: Revenue grew 13% in 2025, driven by heart-lung machine upgrades and consumables. The company plans to expand manufacturing capacity and launch a next-generation oxygenator by 2028.
Epilepsy Segment: Revenue grew 6% in 2025, with strong growth in Europe and Rest of World regions. Improved reimbursement in the U.S. is expected to expand patient access and drive growth in 2026.
Revenue Growth: Achieved double-digit organic revenue growth in 2025, marking the third consecutive year of such growth.
Operational Efficiency: Expanded adjusted operating margins by 150 basis points in 2025, driven by revenue growth and cost management.
Strategic Investments: Investments in innovation, including digital health platforms and next-generation products, are aimed at entering high-growth markets and improving long-term profitability.
Leadership Strengthening: Appointed Lucile Blaise as Global Head of Commercialization for OSA to enhance leadership capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cardiopulmonary segment: Some planned Essenz placements and tender activity for the quarter shifted into 2026, moderating the fourth quarter contribution. Strong demand for oxygenators continues to outpace the market's ability to supply, creating supply chain challenges. Tariff impacts and unfavorable currency changes also affected adjusted gross margin.
Epilepsy segment: Despite strong growth, there are barriers to access and procedure penetration for VNS therapy, particularly for Medicaid patients. Historical hospital rates for Medicaid patients did not fully cover VNS therapy procedure costs, though reimbursement improvements are expected to address this.
Obstructive Sleep Apnea (OSA) program: The OSA program faces regulatory hurdles, including pending PMA approval for the clinical trial device and a PMA supplement for the MRI-compatible device. The commercial launch timeline is dependent on these approvals, which could delay market entry.
Difficult-to-treat depression (DTD): Reimbursement uncertainty with CMS remains a challenge, as the company is still working towards submitting a reconsideration package. This creates uncertainty in advancing the program.
Tariffs and currency impacts: Tariffs and unfavorable currency changes have negatively impacted adjusted gross margin and operating income. The company estimates a tariff net impact of less than $5 million on adjusted operating income for the full year.
SNIA litigation: The company faces a potential $400 million payment related to the SNIA litigation, which could impact cash flow and earnings per share in 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cardiopulmonary Revenue Growth: For 2026, cardiopulmonary revenue is expected to grow 7% to 8%, driven by continued HLM growth, Essenz penetration globally, strong demand for consumables, and expanded manufacturing capacity.
Epilepsy Revenue Growth: For 2026, epilepsy revenue is forecasted to grow 5.5% to 6.5%, with mid-single-digit growth in the U.S. and high single-digit growth in Europe and Rest of World regions.
Overall Revenue Growth: LivaNova is guiding full-year 2026 revenue growth between 6% and 7% on a constant currency basis, consistent with the 2025 to 2028 framework.
Adjusted Operating Income Margin: For 2026, adjusted operating income margin is estimated to be between 20% and 21%.
Adjusted Diluted Earnings Per Share: Projected to be in the range of $4.15 to $4.25 for 2026, representing approximately 8% growth at midpoint.
Adjusted Free Cash Flow: Expected to be in the range of $160 million to $180 million for 2026, including $120 million in capital spending.
Capital Expenditures: Capital spending for 2026 is projected at $120 million, supporting cardiopulmonary capacity expansion, next-generation oxygenator manufacturing scale-up, and IT infrastructure investments.
Obstructive Sleep Apnea (OSA) Program: PMA approval for the clinical trial device is expected in the first half of 2026, followed by a PMA supplement for the commercial MRI-compatible device. A limited market release of the MRI-compatible device is planned for the first half of 2027, with a broader commercial launch in the second half of 2027.
Epilepsy Digital Health Platform: A limited market rollout of the clinician portal is expected in 2026, with a full market release planned for 2027 alongside the launch of the next-generation Bluetooth-enabled implantable pulse generator.
Difficult-to-Treat Depression (DTD) Reimbursement: LivaNova is actively working with CMS to submit a reconsideration package for reimbursement, with submission timing yet to be finalized.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you help us think about how you're thinking about oxys versus HLM growth in '26?
A:The growth drivers for '26 are expected to be the same as last year: Essenz upgrades, market share gains in consumables, and price. Essenz upgrades are expected to drive approximately double-digit growth, with market share gains continuing. Conservative assumptions have been made regarding the price premium for Essenz and oxygenator output due to third-party supply constraints.
Q:Any color on the shifting of the tenders from Q4 to '26?
A:The shift in tenders from Q4 to '26 was not material and will be fully recaptured in the first quarter. It is fully incorporated into the full-year guidance.
Q:What is baked into the guide for the epilepsy business for the year?
A:The guide includes tailwinds from reimbursement improvement (close to 50% on new and replacement implants) and strong clinical results from the core VNS study. Price will be a short-term contributor to growth, but increased penetration will take time. Two-thirds of U.S. epilepsy revenue comes from replacement implants, providing a durable revenue stream.
Q:Can you comment on the WISeR program and its impact on the VNS business?
A:No denials have been observed in the Medicare patient population cohorts being tracked. A significant portion of Medicare patients fall under the Medicare Advantage plan, which requires prior authorization, so no dramatic changes are expected for the business.
Q:Can you provide more specifics on the HLM tender timing and the Essenz opportunity in China?
A:The shift in HLM placements was immaterial and will be fully captured in Q1 or Q2. In China, the Essenz launch is progressing as planned, with China being the second-largest market for placed units and a current win rate above 80%. Essenz placements are expected to increase from 55% to 80% this year, with China being a significant driver.
Q:What is the window for replacement implants in the U.S. epilepsy business, and could financial incentives lead to more replacements?
A:The reimbursement improvement for end-of-service supports the penetration of new patient implants rather than promoting a step-up in replacements. The focus remains on expanding penetration across the account universe.
Q:How does the CMS decision on HGNS procedures impact VNS reimbursement and the HGNS opportunity?
A:The CMS decision ensures that VNS therapy for epilepsy has a separate code from HGNS or OSA. The company is advocating for a Level 6 APC classification for VNS therapy. For HGNS, the company will use the most prevailing codes at the time of launch, with no risk anticipated for reimbursement.
Q:What feedback has been received from customers regarding reimbursement changes?
A:Early progress has been seen in reopening closed accounts, expanding penetration in existing accounts, and renegotiating volume-based discounts. The impact on price is expected to be more significant than on volume.
Q:What is the outlook for RECOVER and depression reimbursement?
A:Depression is expected to share the same code as VNS therapy. The company is advocating for a Level 6 APC classification for VNS therapy, but it is too early to comment on ASPs as the reimbursement decision from CMS is still pending.
Q:What is the focus of R&D spend in 2026?
A:R&D investment will focus on next-generation Bluetooth-enabled IPG for epilepsy (launch in 2027), next-gen oxygenator and HLM hardware enhancements for cardiopulmonary (launch in '27-'28), and next-gen OSA device development (launch in the second half of '27).
Q:What is the impact of current OSA reimbursement on the 2027 launch?
A:The current coding guided by CMS is sufficient for a meaningful growth opportunity. The company remains excited about the differentiated technology and clinical outcomes in the OSA space.
Q:What investments are being made in 2026 for the OSA business?
A:Investments include finalizing the PolySync clinical piece, obtaining FDA approval for the clinical trial device, and developing the MRI-compatible commercial launch device. Commercial organization investments will be limited in 2026, with broader expansion planned for 2027.
Q:Why is the guidance for 2026 lower than the double-digit growth of the past three years?
A:The guidance reflects conservative assumptions, including a moderation in the price premium on Essenz and constraints on oxygenator output due to third-party supply issues. There are no negative dynamics, and the guidance is consistent with past philosophy.
Q:What is the status of Medicaid reimbursement changes for epilepsy?
A:Medicaid reimbursement is expected to follow Medicare, but it will take time to work through individual state situations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the geographies affected by the HLM tender timing shift, stating only that it was immaterial and would be recaptured in Q1 or Q2. Additionally, they did not provide clarity on ASPs for depression reimbursement, citing the pending CMS decision. The response to the question about R&D spend in Q4 lacked specific details on the drivers of the increase, only providing a general overview of 2026 priorities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ahmet
Bluetooth generator
Connected Care
HGNS
Investor Day
LivaNova digit
Lucile
MRI device
algorithm
assumption
barrier access
care
chapter
clinician portal
cloud
evidence momentum
expansion generation
framework Investor
health platform
manufacturing scale
market release
mid
momentum OSA
neuromodulation capability
nonresponders responder
patient PolySync
road map
rollout
tariff
teen
titration
workflow
LIVN Transcript
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary highlights increased guidance across multiple financial metrics, including revenue and EPS, alongside strategic growth in cardiopulmonary and epilepsy segments. The Q&A section reveals positive analyst sentiment and confidence in management's ability to execute on guidance, with no major risks identified. The company's proactive approach to reimbursement changes and product launches further supports a positive outlook. Despite conservative assumptions for 2026, the current guidance and market strategy suggest a likely positive stock price movement in the near term.
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call presents a positive outlook with raised guidance for revenue growth, EPS, and free cash flow. The Q&A section highlights strategic investments in capacity expansion and new product launches, despite some conservative Q4 guidance. The positive feedback on the Essenz launch in China and the anticipated Medicare reimbursement increase for epilepsy therapy further support a positive sentiment. Although management avoided some specifics, the overall sentiment is positive, considering the strategic initiatives and growth prospects.
LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
LIVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
